SCHEMBL277488

SCHEMBL277488

COC(=O)Oc1ccc(-c2nc3ccc(O)cc3c(=O)[nH]2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNKS O95271 6/20 0.51
GUSB P08236 6/20 0.51
PARP1 P09874 5/20 0.51
TNKS2 Q9H2K2 5/20 0.51
NPC1 O15118 1/20 0.51
CASP3 P42574 1/20 0.51
RAB9A P51151 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
CYP1A1 P04798 2/20 0.46
CYP1B1 Q16678 2/20 0.46
CYP1A2 P05177 1/20 0.46
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13298758 0.83 TNKS (0.72) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL11099539 0.82 GUSB (0.64) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL259526 0.79 TNKS (0.59) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL259248 0.76 TNKS (0.58) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL28463042 0.76 TNKS (0.74) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL17254841 0.75 TNKS (0.64) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL259566 0.75 TNKS (0.66) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL11388577 0.75 CHEK2 (0.69) TNKSGUSBPARP1TNKS2NPC1
SCHEMBL259557 0.75 CYP1A1 (0.57) TNKSGUSBPARP1TNKS2KDM4E
SCHEMBL259542 0.74 KDM4E (0.56) TNKSGUSBPARP1TNKS2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A TNKS 578/4885GUSB 1751/4885PARP1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.